Printed From BioPortfolio.com
[News] Adding radiotherapy to chemotherapy in advanced NSCLC
23:16 EDT 28 Sep 2017 | The Lancet
Consolidative, non-invasive, stereotactic ablative radiotherapy (SABR) given before maintenance chemotherapy significantly improves progression-free survival in patients with limited metastatic non-small-cell lung cancer and no actionable mutations for targeted therapy, compared with maintenance chemotherapy alone, according to an interim analysis of a phase 2 randomised trial.
Original Article: [News] Adding radiotherapy to chemotherapy in advanced NSCLC
